Age 9 - 18 years consistent with criteria-defined NAFLD hepatic steatosis which exclude other conditions of hepatic steatosis e.g., genetic disorders (such as fatty acid oxidation defects, mitochondrial disorders, citrin deficiency, Wilson disease, and lysosomal acid lipase deficiency), metabolic disorders (uncontrolled diabetes mellitus, familial combined hyperlipidemia), drugs (amiodarone, corticosteroids, methotrexate, antipsychotic drugs and valproic acid), dietary or toxin causes (severe pr
Conditions
Interventions
Probiotics will be given to the enrolled children in the probiotics group with one capsule once daily for 3 months. We will collect the potential probiotics-related adverse reactions and other health
Active Comparator Drug,No Intervention No treatment
Probiotics group,Controlled group
Sponsors
Faculty of Medicine Ramathibodi Hospital Mahidol University
Eligibility
Sex/Gender
All
Age
9 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Age 9 - 18 years consistent with criteria-defined NAFLD hepatic steatosis which exclude other conditions of hepatic steatosis e.g., genetic disorders (such as fatty acid oxidation defects, mitochondrial disorders, citrin deficiency, Wilson disease, and lysosomal acid lipase deficiency), metabolic disorders (uncontrolled diabetes mellitus, familial combined hyperlipidemia), drugs (amiodarone, corticosteroids, methotrexate, antipsychotic drugs and valproic acid), dietary or toxin causes (severe protein-energy malnutrition, alcohol abuse, and parenteral nutrition) and infections or MASLD 2. Able to swallow capsule
Exclusion criteria
Exclusion criteria: 1) Preexisting liver disease or new concomitant liver disease(s) 2) Genetic disease that may predisposed to have steatotic liver diseases such as familial hypocholesterolemia, lipodystrophy, citrin deficiency, Wilson disease and lysosomal acid lipase deficiency 3) Bedridden or bed-bound 4) Antibiotics prophylaxis uses more than 6 months before enrollment 5) Immunosuppressive drug use/Chemotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALT alteration 3 month and 6 month Blood test | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometry, inflammatory and metabolic profiles, and liver ultrasonography on fat quantification 3 month and 6 month Blood test, Ultrasonography | — |
Countries
Thailand
Contacts
Public ContactPornthep Tanpowpong
Faculty of Medicine Ramathibodi Hospital
Outcome results
None listed